Robots & Robotics

J&J Names Memorial Hermann as OTTAVA’s First Commercial Customer

Memorial Hermann-Texas Medical Center will be the first hospital to install J&J’s OTTAVA surgical robot under its early-access commercial program.

By Rachel Whitman | Edited by Daniel Krauss Published:
J&J Names Memorial Hermann as OTTAVA’s First Commercial Customer
Memorial Hermann will be the first commercial hospital to install the OTTAVA surgical robot. Photo: Johnson & Johnson

Key Notes

  • Memorial Hermann-Texas Medical Center will become the first hospital to install OTTAVA through the early-access commercial program.
  • The surgeon-controlled platform integrates four robotic arms into a surgical table and received FDA De Novo authorization in July.
  • The November announcement names the first commercial site, while installation timing, pricing and the number of early-access systems remain undisclosed.

Johnson & Johnson has named Memorial Hermann-Texas Medical Center in Houston as the first hospital that will install its OTTAVA robotic surgical system under an early-access commercial program. The agreement moves the table-integrated platform toward commercial hospital use after its U.S. regulatory authorization in July.

The November 19 announcement describes an installation still to come. It does not give an installation date, price or total number of systems in the early-access program.

Four Robotic Arms Built Into the Surgical Table

OTTAVA incorporates four robotic arms into a standard-sized surgical table. J&J designed the arrangement to address operating-room space and workflow requirements, combining the table, surgical instrumentation and software-controlled features in one platform.

In its development overview, the company also describes connectivity with the Polyphonic digital ecosystem for surgical data, video and devices. Its official platform video shows the system’s architecture; that introduction predates this hospital announcement.

The integration is relevant to how a surgical team works around the patient as well as how the instruments move. Room layout, patient access and equipment coordination are part of putting a robotic system into routine service. J&J’s claimed efficiency benefits will need to be assessed in actual hospital operation.

FDA Authorization Preceded the Commercial Agreement

The FDA’s device record confirms that OTTAVA received De Novo authorization on July 21, 2026. The regulator classified it as a Class II integrated operating table-electromechanical surgical system.

The accompanying FDA order specifies adult use by trained physicians in an operating-room environment for labeled upper-abdominal laparoscopic procedures. It also describes repositioning the patient through table movement without undocking.

This remains a surgeon-controlled surgical tool. Software-enabled automation supports the platform’s operation; it does not establish independent diagnosis or a robot performing surgery without a trained physician.

A Clinical Partner Becomes the First Commercial Site

Memorial Hermann-Texas Medical Center previously served as an investigational clinical site for OTTAVA. The commercial agreement builds on that collaboration rather than marking the system’s first use in a clinical study.

J&J plans to introduce OTTAVA through selected U.S. customers while evaluating additional indications. The first named hospital creates a setting in which to examine training, equipment integration and day-to-day workflow beyond the investigational program.

RobotsBeat’s coverage of MedStar’s single-port program follows another surgical-robotics platform entering different hospital workflows. Those procedures do not provide a comparison with OTTAVA, but illustrate why adoption depends on the particular system, procedure and clinical team.

For OTTAVA, the immediate commercial milestone is a named early-access customer. Completed installation and evidence from subsequent hospital use are the next steps to follow.

Disclaimer: RobotsBeat is an independent media brand owned and operated by NuvexMedia LLC, publishing news, research, and insights on artificial intelligence, emerging technologies, automation, and related industries. NuvexMedia LLC invests in and collaborates with companies across the AI, Robotics, technology, software, and digital innovation sectors. These relationships do not influence RobotsBeat's editorial coverage, and the publication maintains full editorial independence to provide accurate, timely, and objective information. © 2026 NuvexMedia LLC. All rights reserved. This content is for informational purposes only and should not be considered legal, tax, investment, financial, or other professional advice.

Business & Markets, News, Robots & Robotics, Science & Tech